ArticleScientific reports2021
Associations between lifetime classic psychedelic use and cardiometabolic diseases.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Exploring self-reported health behavior change following naturalistic psychedelic use.Journal of health psychology · 2026Article
- Association Between Lifetime Hallucinogen Use and Valvular Heart Disease: Findings from the All of Us Research Program.Journal of psychoactive drugs · 2026Article
- The combination of exercise and psychedelics for the treatment of major depressive disorder.Discover mental health · 2026Article
- Exploring practitioners' perceptions of health behavior changes associated with psychedelic experiences.Scientific reports · 2025Article
- Health-related behavioral changes following the use of psychedelics in naturalistic settings.Preventive medicine reports · 2025Article
- Lysergic Acid Diethylamide (LSD) and the Heart: Exploring the Potential Impacts of LSD on Cardiovascular Function.Cureus · 2025Review
- Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.Journal of racial and ethnic health disparities · 2025Article
- The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress.Healthcare (Basel, Switzerland) · 2025Article
- The compulsive eating paradigm: can psychedelics help in treating obesity?Journal of eating disorders · 2025Review
- Is there a place for psychedelics in sports practice?Acta neuropsychiatrica · 2025Review
- Cardiovascular effects and safety of classic psychedelics.Nature cardiovascular research · 2025Review
- Psilocybin: From Psychiatric Pariah to Perceived Panacea.The American journal of psychiatry · 2025Review
- Article
- Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.Neuropharmacology · 2023Review
- Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.Frontiers in psychiatry · 2023Article
- Psychedelics and workplace harm.Frontiers in psychiatry · 2023Article
- Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.International journal of environmental research and public health · 2022Article
- Psychedelics in the treatment of unipolar and bipolar depression.International journal of bipolar disorders · 2022Review
- Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.Scientific reports · 2022Article
- Classic psychedelics, health behavior, and physical health.Therapeutic advances in psychopharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005-2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65-0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78-0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.